-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-08-28
Values as of: 2024-08-28
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Company Website : www.spdrs.com
Currency: USD
Country : USA
Inception Date: 31/01/2006
Primary Benchmark: S&P Biotechnology Select Industry TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.35%
Management Expense Ratio: 0.35 %
N/A
N/A
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
+0.32 (+0.21%) |
USD 42.19B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
+0.19 (+0.26%) |
USD 3.02B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
+0.86 (+0.77%) |
USD 1.26B |
| XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
+1.16 (+1.31%) |
USD 0.22B |
| IDNA | iShares Genomics Immunology an.. | 0.00 % |
+0.65 (+2.67%) |
USD 0.14B |
| SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
+1.20 (+3.25%) |
USD 0.11B |
| XHS | SPDR® S&P Health Care Service.. | 0.35 % |
+1.71 (+1.78%) |
USD 0.08B |
| HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
+0.32 (+1.10%) |
USD 0.06B |
| BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
+1.33 (+2.12%) |
USD 0.02B |
| BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
+0.96 (+3.42%) |
USD 0.01B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| INAV | 10.00 % | 0.00 % |
N/A |
N/A | |
| MATH | Metalpha Technology Holdi.. | 0.00 % | 1.35 % |
N/A |
USD 0.04B |
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 12.60% | 57% | F | 71% | C- | ||
| Dividend Return | 0.13% | 20% | F | 2% | F | ||
| Total Return | 12.73% | 62% | D | 65% | D | ||
| Trailing 12 Months | |||||||
| Capital Gain | 26.18% | 95% | A | 83% | B | ||
| Dividend Return | 0.16% | 17% | F | 2% | F | ||
| Total Return | 26.34% | 95% | A | 80% | B- | ||
| Trailing 5 Years | |||||||
| Capital Gain | 25.10% | 33% | F | 58% | F | ||
| Dividend Return | 0.52% | 28% | F | 1% | F | ||
| Total Return | 25.61% | 29% | F | 48% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 2.68% | 33% | F | 50% | F | ||
| Dividend Return | 2.76% | 33% | F | 40% | F | ||
| Total Return | 0.08% | 26% | F | 2% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 32.95% | 19% | F | 30% | F | ||
| Risk Adjusted Return | 8.39% | 24% | F | 32% | F | ||
| Market Capitalization | 3.15B | N/A | N/A | N/A | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
